TY - JOUR
T1 - Addressing risk management difficulties in children with food allergies
AU - Eigenmann, Philippe A.
AU - Ebisawa, Motohiro
AU - Greenhawt, Matthew
AU - Hourihane, Jonathan O.B.
AU - Perry, Tamara T.
AU - Remington, Benjamin C.
AU - Wood, Robert A.
N1 - Funding Information:
PAE received speaker's honoraria and research support from Thermo Fisher Scientific, consultant fees from Nestlé, Abbott, and DBV Technologies, reports royalty payments from UpToDate and Elsevier, and holds stock options in DBV Technologies. ME received speaker's honoraria from DBV Technologies and Mylan. MG is supported by grant #5K08HS024599‐02 from the Agency for Healthcare Research and Quality; is an expert panel and coordinating committee member of the NIAID‐sponsored Guidelines for Peanut Allergy Prevention; has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, Glaxo Smith Kline, Merck, Nutricia, Kaleo Pharmaceutical, Nestle, Aquestive, Allergy Therapeutics, Allergenis, Aravax, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune Therapeutics, DBV Technologies, Before Brands, multiple state allergy societies, the American College of Allergy Asthma and Immunology, the European Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters. JOBH receives consultant fees and research funding from Aimmune Therapeutics, and research funding from DBV Technologies and from Johnson& Johnson. TTP receives research grant funding from the National Institutes of Health. BCR received research support and consultant fees from DBV Technologies. RAW receives research funding from NIAID, Aimmune, Astellas, DBV technologies, Regeneron, Sanofi, and Genentech, and royalties from UpToDate.
PY - 2021
Y1 - 2021
N2 - Risk is a concept inherent in every medical procedure. It can be defined as the probability of an adverse event in a defined population over a specified period of time. In the frame of food allergy management, it might be related to a diagnostic procedure, a treatment, or the consumption of foods. The risk of an adverse event can also be augmented by individual factors. This rostrum article discusses various aspects faced by children with food allergies in the light of risk, and their practical implications. Identifying personal risks for severe reaction, such as unstable asthma, and correcting them whenever possible also contribute to a reduction of the risk inherent to food allergy. Among the facets discussed, oral food challenges (OFC) are the most common diagnostic procedures implying an inherent risk. The risk of OFCs can be minimized by correct indication and timing of the test, a safe setting, as well as by ensuring that the patient is otherwise well without potential stressor potentially increasing the risk of a more severe reaction. Oral immunotherapy (OIT) has been studied as a potential treatment for increasing the threshold dose for reaction, and thus reducing the risk of accidental reaction. Nevertheless, the procedure is not devoid of risk as the patients may and do often react during the course of the procedure. Ingestion of trace amounts in processed foods, mainly in community settings such as restaurants, schools, or day care, represents a potential risk of reactions, although for a minority of patients. Precautionary allergen labeling (PAL) is a widespread strategy to reduce the potential risk of reactions due to traces. However, PAL is currently inefficient due to inconsistent labeling, also not indicating a clear maximum amount possibly present in the manufactured food. Finally, cost-effectiveness needs to be considered in risk management, as many risk reduction procedures are clearly not cost-effective.
AB - Risk is a concept inherent in every medical procedure. It can be defined as the probability of an adverse event in a defined population over a specified period of time. In the frame of food allergy management, it might be related to a diagnostic procedure, a treatment, or the consumption of foods. The risk of an adverse event can also be augmented by individual factors. This rostrum article discusses various aspects faced by children with food allergies in the light of risk, and their practical implications. Identifying personal risks for severe reaction, such as unstable asthma, and correcting them whenever possible also contribute to a reduction of the risk inherent to food allergy. Among the facets discussed, oral food challenges (OFC) are the most common diagnostic procedures implying an inherent risk. The risk of OFCs can be minimized by correct indication and timing of the test, a safe setting, as well as by ensuring that the patient is otherwise well without potential stressor potentially increasing the risk of a more severe reaction. Oral immunotherapy (OIT) has been studied as a potential treatment for increasing the threshold dose for reaction, and thus reducing the risk of accidental reaction. Nevertheless, the procedure is not devoid of risk as the patients may and do often react during the course of the procedure. Ingestion of trace amounts in processed foods, mainly in community settings such as restaurants, schools, or day care, represents a potential risk of reactions, although for a minority of patients. Precautionary allergen labeling (PAL) is a widespread strategy to reduce the potential risk of reactions due to traces. However, PAL is currently inefficient due to inconsistent labeling, also not indicating a clear maximum amount possibly present in the manufactured food. Finally, cost-effectiveness needs to be considered in risk management, as many risk reduction procedures are clearly not cost-effective.
KW - anaphylaxis
KW - children
KW - diagnosis
KW - food allergy
KW - oral food challenges
KW - oral tolerance induction
KW - risk assessment
UR - http://www.scopus.com/inward/record.url?scp=85100848860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100848860&partnerID=8YFLogxK
U2 - 10.1111/pai.13455
DO - 10.1111/pai.13455
M3 - Article
C2 - 33480057
AN - SCOPUS:85100848860
JO - Pediatric Allergy and Immunology
JF - Pediatric Allergy and Immunology
SN - 0905-6157
ER -